ArticleFrontiers in oncology2025
Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Article
- 3D bioprinting innovations: a new frontier in breast cancer research.Medical oncology (Northwood, London, England) · 2025Review
- Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HER2 expression has a central role in breast cancer carcinogenesis and is associated with poor prognosis. Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemotherapy and includes cancers with immunohistochemistry (IHC) 1+or 2+with negative fluorescence Methods: HER2-low BC patients diagnosed and treated in the Harbin Medical University Cancer Hospital from January 2012 to December 2018 were included. Relevant clinical and pathological characteristics were included, and baseline and preoperative complete blood cell counts were evaluated to calculate four systemic immune-inflammatory markers: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII). The optimal cutoff values for these markers were determined using ROC curves and patients were classified into high-value and low-value groups based on these cutoff values. Univariate and multivariate logistic regression analyses were conducted to analyze factors influencing axillary pCR. The factors with independent predictive value were used to construct a forest map. Results: A total of 998 patients were included in the study. 35.6% (355 of 998) of patients achieved axillary pCR after NAC. The result of multivariate logistic regression analysis showed that Estrogen receptor (ER) (OR=2.18; 95% CI 1.43-3.32; P<0.001),pathology type (OR=0.51; 95% CI 0.40-0.65; P<0.001),baseline platelet (OR=1.45; 95% CI 1.02-2.05; P=0.037),preoperative PLR (OR=1.63; 95% CI 1.01-2.64; P=0.046) were significant independent predictors of ypN0. Conclusion: The forest map for predicting axillary pCR incorporates four variables, including ER, pathology type, platelet, platelet-to-lymphocyte ratio (PLR). In patients treated with NAC, a higher baseline platelet and a higher preoperative PLR was associated with a higher incidence of axillary pCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.